Details of the Drug Reposition

General Information of This Drug (ID: DM4BDON)

• Drug Name: Methylprednisolone (DM4BDON)
• Synonyms: Depo-medrol; M-predrol; Medrol; Medrol Acetate
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

39 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Serum sickness	DIS0MRKJ	N.A.	Approved	[1]
Rheumatic heart disease	DISCI8JQ	N.A.	Approved	[1]
Primary cutaneous T-cell lymphoma	DIS35WVW	N.A.	Approved	[1]
Miliary tuberculosis	DIS4AT5W	N.A.	Approved	[1]
Microscopic polyangiitis	DIS74KSO	N.A.	Approved	[1]
Leukemia	DISNAKFL	N.A.	Approved	[1]
Granuloma annulare	DISMOUMI	N.A.	Approved	[1]
Exanthem	DISAFOQN	N.A.	Approved	[1]
Erythema multiforme	DISKCLM1	N.A.	Approved	[1]
Epicondylitis	DIS0R2VM	N.A.	Approved	[1]
Disorder of orbital region	DISH0ECJ	N.A.	Approved	[1]
Diamond-Blackfan anemia	DISI2SNW	N.A.	Approved	[1]
Chronic graft versus host disease	DIS1MM9J	N.A.	Approved	[1]
Bursitis	DISCF7Y9	N.A.	Approved	[1]
Aspiration pneumonitis	DIS5S4DE	N.A.	Approved	[1]
Acute adrenal insufficiency	DIS66YLV	N.A.	Approved	[1]
Myeloproliferative neoplasm	DIS5KAPA	2A20	Approved	[1]
Mycosis fungoides	DIS62RB8	2B01	Approved	[1]
Autoimmune haemolytic anaemia	DIS7MS3M	3A20	Approved	[1]
Angioedema	DIS90QDN	4A00.15	Approved	[1]
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Approved	[1]
Sarcoidosis	DISE5B8Z	4B20.5	Approved	[1]
Congenital adrenal hyperplasia	DISG873W	5A71.01	Approved	[1]
Addison disease	DIS7HNOH	5A74.0	Approved	[1]
Multiple sclerosis	DISB2WZI	8A40	Approved	[1]
Cerebral edema	DIS4GHSB	8D60.1	Approved	[1]
Seasonal allergic rhinitis	DIS58KQX	CA08.01	Approved	[1]
Severe asthma	DISAVQI3	CA23	Approved	[1]
Pneumocystis pneumonia	DISFSOM3	CA40.20	Approved	[1]
Ischemia-reperfusion injury	DISG8CCO	DB98.B	Approved	[1]
Crohn disease	DIS2C5Q8	DD70	Approved	[1]
Inflammatory bowel disease	DISGN23E	DD72	Approved	[1]
Skin disease	DISDW8R6	EA00-EM0Z	Approved	[1]
Psoriasis	DIS59VMN	EA90	Approved	[1]
Dermatitis herpetiformis	DIS0TC0G	EB44	Approved	[1]
Rheumatoid arthritis	DISTSB4J	FA20	Approved	[2]
Psoriatic arthritis	DISLWTG2	FA21	Approved	[1]
Fever	DISJGEAQ	MG26	Approved	[1]
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Approved	[2]

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 3	[3]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pemphigus	DISZAZ6M	N.A.	Withdrawn	[4]

4 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Thyroiditis	DISTCV24	N.A.	Discontinued in Phase 3	[5]
Glomerulonephritis	DISPZIQ3	5D00.Y	Discontinued in Phase 3	[6]
Atopic dermatitis	DISTCP41	EA80	Discontinued in Phase 3	[7]
Seborrhoeic dermatitis	DISNWVJU	EA81	Discontinued in Phase 3	[8]

8 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Tendinitis	DISS7ANY	N.A.	Discontinued in Phase 2	[9]
Exfoliative dermatitis	DISQEWIW	N.A.	Discontinued in Phase 2	[10]
Tenosynovitis	DISR5H9R	N.A.	Discontinued in Phase 2	[11]
Humoral hypercalcemia of malignancy	DISQQ62D	N.A.	Discontinued in Phase 2	[12]
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Discontinued in Phase 2	[13]
Autoimmune disease	DISORMTM	4A40-4A45	Discontinued in Phase 2	[14]
Musculoskeletal disorder	DISPPN0O	FA00-FC0Z	Discontinued in Phase 2	[15]
Ankylosing spondylitis	DISRC6IR	FA92.0	Discontinued in Phase 2	[16]

2 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Nephrotic syndrome	DISSPSC2	N.A.	Discontinued in Phase 1	[17]
Contact dermatitis	DISQ3AU0	EK0Z	Discontinued in Phase 1	[18]

7 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Trichinellosis	DISUR2ZW	N.A.	Investigative	[1]
Synovitis	DISW2GPY	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	DISV1LU6	N.A.	Investigative	[1]
Beta-thalassemia major	DISW06BV	N.A.	Investigative	[1]
Acquired thrombocytopenia	DISXH01C	N.A.	Investigative	[1]
Follicular lymphoma	DISVEUR6	2A80	Investigative	[1]
Spinal cord injury	DISOR9PQ	ND51.2	Investigative	[19]

References

• [1] Methylprednisolone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT04341038) Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
• [4] "The Evaluation of Stimulant Withdrawal"
• [5] STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients
• [6] An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
• [7] Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
• [8] Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
• [9] A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• [10] Panitumumab and Irinotecan for Malignant Gliomas
• [11] Memantine for Recurrent Glioblastoma
• [12] Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
• [13] Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
• [14] SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
• [15] Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
• [16] A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)
• [17] Sirolimus for Eosinophil-Associated Gastrointestinal Disorders
• [18] A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088).